Metabolic dysfunction–associated steatohepatitis (MASH) is a form of liver disease that can progress ... to evaluate the GLP-1 receptor agonist semaglutide in patients with MASH and stage ...

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Fat cells are also metabolically active and can cause a chronic state of inflammation in the part of the body where they ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Due to its role in managing diabetes, Ozempic, the brand name for the medication semaglutide, is gaining a lot of attention.

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

This health crisis is largely attributed to sedentary lifestyles, excessive consumption of processed and fast food, and ...